A61K 40/33
Antibodies
Official title: Antibodies; T-cell engagers
A61K40/33 (Antibodies) appears on 19 US grants and 166 published applications in this corpus.
Search patents in A61K- Granted patents
- 19
- Published applications
- 166
- Assignees
- 121
- Inventors
- 503
- Latest grant
- 11 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 2002 | 0 | 1 |
| 2003 | 0 | 1 |
| 2004 | 0 | 0 |
| 2005 | 0 | 0 |
| 2006 | 0 | 0 |
| 2007 | 0 | 1 |
| 2008 | 0 | 0 |
| 2009 | 0 | 1 |
| 2010 | 1 | 0 |
| 2011 | 0 | 1 |
| 2012 | 0 | 0 |
| 2013 | 0 | 0 |
| 2014 | 0 | 0 |
| 2015 | 0 | 0 |
| 2016 | 0 | 1 |
| 2017 | 0 | 1 |
| 2018 | 0 | 2 |
| 2019 | 0 | 4 |
| 2020 | 0 | 3 |
| 2021 | 2 | 3 |
| 2022 | 0 | 11 |
| 2023 | 1 | 38 |
| 2024 | 3 | 32 |
| 2025 | 5 | 38 |
| 2026 | 7 | 28 |
By publication year. 2026 runs to 8 Oct.
Recent patents
- Anti-CD22 single domain antibodies and therapeutic constructs11 Aug 2026US 12,703,744 B2National Research Council of Canada
- Anti-BST2 antibodies targeting BST2 long isoform4 Aug 2026US 12,698,335 B2Board of Regents, The University of Texas System
- Prevention or mitigation of T-cell engaging agent-related adverse effects19 May 2026US 12,629,419 B2Hoffmann-La Roche Inc.
- Treatments administering chimeric IgG Fc receptor comprising an extracellular domain of CD6431 Mar 2026US 12,590,138 B2Regents of the University of Minnesota
- CD3-specific binding molecules31 Mar 2026US 12,590,152 B2Immunocore Limited
- T-cell receptors targeting her2 and methods of use thereof1 Oct 2026US 2026/0297158 A1Board of Regents, The University of Texas System
- In vivo daric17 Sep 2026US 2026/0273058 A1Kelonia Therapeutics, Inc.
- Cd40-targetting antibodies and uses thereof3 Sep 2026US 2026/0256913 A1Utc Tyherapeutics (Shangnai) Co., Ltd.
- Synthetic antigen receptors for covalent immune recruiters and methods and uses thereof27 Aug 2026US 2026/0248852 A1McMaster University
- Cnx antigen-binding molecules27 Aug 2026US 2026/0250378 A1Agency for Science, Technology and Research
Most cited
By later US patents
- In situ immunization53US 7,763,243 B2Roger Williams Medical Center · 2010
- Reducing immune inhibition induced by SIGLEC-156US 11,104,732 B2Innovative Cellular Therapeutics Holdings, Ltd. · 2021
- Methods and compositions for cells expressing a chimeric intracellular signaling molecule6US 11,890,301 B2The Trustees of the University of Pennsylvania · 2024
- Methods for engineering allogeneic T cell to increase their persistence and/or engraftment into patients3US 11,186,824 B2Cellectis · 2021